USC and Ellison Medical Institute Partner to Advance Prostate Cancer Drug
USC Stevens Center for Innovation shared a post on LinkedIn:
“We’re thrilled to announce that the University of Southern California has entered into an exclusive licensing agreement with the Ellison Medical Institute (EMI) for the rights to develop and commercialize a novel therapeutic drug for the treatment of prostatecancer and related diseases.
USC Department of Chemistry Professor Charles McKenna, Co-Director of the USC Center for New Technologies in Drug Discovery and Development, and Professor David Agus at Keck School of Medicine of the University of Southern California and EMI Founding CEO, created a joint research project to discover small molecule androgen receptor modulators targeting advanced prostate cancer. Their efforts have resulted in the identification of several promising candidates for clinical translation while offering graduate students a unique opportunity to engage in interdisciplinary research early in their careers.
USC Stevens is proud to be part of another collaboration that is bringing hope to cancer patients. Read more.
Photo Credit: Ellison Medical Institute.”
Erin Overstreet, Executive Director at USC Stevens Center for Innovation, shared a post on LinkedIn by USC Stevens Center for Innovation, adding:
“An exciting partnership between world-class researchers and institutions.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023